6698-46-0

Usage

Uses

Used in Pharmaceutical Industry:
5-O-Benzoyl-1,2-O-isopropylidene-alpha-D-erythro-pent-3-ulofuranose is used as a key intermediate in the chemical synthesis of D-ribose, an essential component of nucleic acids and various other biological molecules. Its role in the synthesis process is crucial for the production of pharmaceuticals and other healthcare products.
Used in Biochemistry Research:
5-O-Benzoyl-1,2-O-isopropylidene-alpha-D-erythro-pent-3-ulofuranose is also utilized in the preparation of methylated nucleoside derivatives, which are important for studying the structure and function of nucleic acids and their interactions with proteins. The synthesis of these derivatives contributes to a better understanding of molecular biology and the development of new therapeutic agents.

InChI:InChI=1/C15H16O6/c1-15(2)20-12-11(16)10(19-14(12)21-15)8-18-13(17)9-6-4-3-5-7-9/h3-7,10,12,14H,8H2,1-2H3

Upstream product

• 6022-96-4 5-O-benzoyl-α-D-xylofuranose 
• 58-86-6 D-xylose 
• 79-37-8 oxalyl dichloride 
• 16749-42-1 5,6-dideoxy-1,2-O-isopropylidene-α-D-xylo-hexofuranose 
• 532-20-7 D-xylofuranose 
• 98-88-4 benzoyl chloride 
• 67-64-1 acetone 
• 20881-04-3 1,2:3,5-di-O-isopropylidene-D-xylofuranose 
• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 

Downstream Products

• 28007-97-8 (6R)-5t-benzoyloxymethyl-2,2-dimethyl-(3at,6rN,6at)-dihydro-spiro[furo[2,3-d][1,3]dioxole-6,4'-imidazolidine]-2',5'-dione 
• 161821-79-0 1,2-isopropylidene-3-C-dimethylphosphono-5-O-benzoyl-α-D-ribofuranose 
• 250588-64-8 Benzoic acid (3aR,5R,6R,6aR)-6-cyano-6-hydroxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-ylmethyl ester 
• 130250-06-5 5-O-benzoyl-1,2-O-isopropylidene-3-C-<(benzyloxy)methylene>-α-D-ribofuranose 
• 144700-67-4 C₂₆H₂₅NO₇ 
• 37077-81-9 1,2-isopropylidene-α-D-ribofuranose 
• 29781-91-7 (E/Z)-5-O-Benzoyl-3-deoxy-3-hydroxyimino-1,2-O-isopropylidene-α-D-erythro-pentofuranose 
• 34304-33-1 5-O-benzoyl-1,2-O-isopropylidene-3-deoxy-3-nitro-D-ribofuranose 
• 34304-34-2 5-O-benzoyl-1,2-O-isopropylidene-3-deoxy-3-nitro-D-xylofuranose 
• 162894-32-8 ((3aR,5R,6R,6aR)-6-hydroxy-2,2-dimethyl-6-(trifluoromethyl)tetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl benzoate 
• 59896-02-5 ((3aR,5S,6aR)-2,2-dimethyl-6-methylenetetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl benzoate 
• 237070-16-5 1,2-O-isopropylidene-5-O-benzoyl-3-C-cyano-α-D-xylofuranose 
• 64775-10-6 ((3aR,5S,6aR)-2,2-dimethyl-6-methylene-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 6612-91-5 ((3aR,5R,65,6aR)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl benzoate 

Relevant academic research and scientific papers

Stereoselective synthesis of new higher carbon sugars from D-xylose

A simple, one-pot multi-step route for the synthesis of a higher carbon sugar 3 by the HDA reaction of a α,β-unsaturated ketone prepared in situ from protected D-xylose with PDC in C6H6 or CH 3CN, followed by the reduction

The Chiron Approach to (3 R,3 aS,6 aR)-Hexahydrofuro[2,3- b]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir

We describe an enantioselective synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol which is a key subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2-O-isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-aldehyde derivative. This optically active ligand alcohol was converted to darunavir efficiently.

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed herein are cyclic di-nucleotide compounds and derivatives thereof that may be useful as STING agonists, and a pharmaceutical composition comprising the same. Also disclosed herein is the process for synthesis and to uses of such cyclic di-nucleo

SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)

The disclosure is directed to crystalline forms of the compound of Formula I, pharmaceutically acceptable salts of the compound of Formula I, and crystalline forms thereof. Pharmaceutical compositions comprising said crystalline forms and salts, as well a

SYNTHESIS OF 1,2,5-TRI-0-BENZ0YL-3-DIBENZYLAMIN0-3-DE0XYRIB0SE AS INTERMEDIATE FOR PRODUCING 3'-AMINO-3'-DEOXYADENOSINE AND 3'-AMINO-3'-DEOXYGUANOSINE AND THE PROTECTED DERIVATIVES THEREOF

The invention generally relates to improved processes for the preparation of intermediates of a cyclic dinucleotide which is useful as a STING agonist.

SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5

The disclosure is directed to methods of treating disease using compounds of Formula (I).

Dimerization of aldosuloses and aldonolactones into branched higher carbon sugars

Homo-dimerizations of a variety of aldosulose and aldonolactone derivatives via aldol and Claisen reactions have been achieved, leading to novel branched higher carbon sugars in a highly stereoselective manner.

Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

CD73 INHIBITORS

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Amipurimycin: Total Synthesis of the Proposed Structures and Diastereoisomers

The proposed diastereoisomers (1 a–d) together with their C8′-epimers (1 e–h) of amipurimycin, a unique antifungal peptidyl nucleoside antibiotic, have been synthesized for the first time. The synthetic approach is efficient and stereodivergent, and features a stereoselective aldol condensation to build the branched C9 sugar amino acid skeleton and a regio- and stereocontrolled gold(I)-catalyzed N-glycosylation to furnish the purine nucleoside. Analysis of the NMR data suggests that the previously assigned configuration of the tertiary C3′ in amipurimycin should be of opposite configuration.